


































1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840.

● ♠ ♦ ♣ ●



L6 ANSWER 6 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN

| | |
|--------------|----------------------|
| Full
Text | String
References |
|--------------|----------------------|

ACCESSION NUMBER: 1998:479505 HCAPLUS
 DOCUMENT NUMBER: 129:122870
 TITLE: Preparation of cycloalkyl, lactam, lactone and related compounds for inhibiting β -amyloid peptide release and/or its synthesis
 INVENTOR(S): Wu, Jing; Tung, Jay S.; Thorsett, Eugene D.; Pleiss, Michael A.; Nissen, Jeffrey S.; Neitz, Jeffrey; Latimer, Lee H.; John, Varghese; Freedman, Stephen; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry, Thomas E.; Dressman, Bruce A.; Cwi, Cynthia L.; Droste, James J.; Henry, Steven S.; Mcdaniel, Stacey L.; Scott, William Leonard; Stucky, Russell D.; Porter, Warren J.
 PATENT ASSIGNEE(S): Athena Neurosciences, Inc., USA; Eli Lilly & Co.
 SOURCE: PCT Int. Appl., 889 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|-----------|-----------------|-------------------------|-----------------|
| <u>WO 9828268</u> | A2 | 19980702 | <u>WO 1997-US22986</u> | 19971222 |
| <u>WO 9828268</u> | A3 | 19981008 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| <u>ZA 9711537</u> | A | 19980625 | <u>ZA 1997-11537</u> | 19971222 |
| <u>CA 2272305</u> | AA | 19980702 | <u>CA 1997-2272305</u> | 19971222 |
| <u>AU 9857007</u> | A1 | 19980717 | <u>AU 1998-57007</u> | 19971222 |
| <u>AU 749658</u> | B2 | 20020627 | | |
| <u>EP 951466</u> | A2 | 19991027 | <u>EP 1997-953208</u> | 19971222 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| <u>CN 1242007</u> | A | 20000119 | <u>CN 1997-180901</u> | 19971222 |
| <u>BR 9714517</u> | A | 20000704 | <u>BR 1997-14517</u> | 19971222 |
| <u>JP 2000511932</u> | T2 | 20000912 | <u>JP 1998-528867</u> | 19971222 |
| <u>NZ 335583</u> | A | 20010330 | <u>NZ 1997-335583</u> | 19971222 |
| <u>CN 1616432</u> | A | 20050518 | <u>CN 2004-10057888</u> | 19971222 |
| <u>TW 568914</u> | B | 20040101 | <u>TW 1997-86119638</u> | 19971223 |
| <u>MX 9905844</u> | A | 20000731 | <u>MX 1999-5844</u> | 19990621 |
| <u>NO 9903098</u> | A | 19990820 | <u>NO 1999-3098</u> | 19990622 |
| <u>US 2002045747</u> | A1 | 20020418 | <u>US 2001-916282</u> | 20010730 |
| <u>US 2002055500</u> | A1 | 20020509 | <u>US 2001-916440</u> | 20010730 |
| <u>US 6653303</u> | B1 | 20031125 | <u>US 2003-336824</u> | 20030106 |
| <u>US 6667305</u> | B1 | 20031223 | <u>US 2003-336745</u> | 20030106 |
| <u>US 6683075</u> | B1 | 20040127 | <u>US 2003-336806</u> | 20030106 |
| <u>US 2004043977</u> | A1 | 20040304 | <u>US 2003-336687</u> | 20030106 |
| <u>US 2004058900</u> | A1 | 20040325 | <u>US 2003-336767</u> | 20030106 |
| <u>US 2005203080</u> | A1 | 20050915 | <u>US 2003-733877</u> | 20031212 |
| <u>US 2005182046</u> | A1 | 20050818 | <u>US 2004-777247</u> | 20040213 |

| | | | | |
|-------------------------------|----|----------|------------------------|-------------|
| <u>US 2005215541</u> | A1 | 20050929 | <u>US 2004-951992</u> | 20040929 |
| <u>US 6951854</u> | B2 | 20051004 | | |
| <u>US 2005272666</u> | A1 | 20051208 | <u>US 2004-1610</u> | 20041202 |
| <u>US 2006079499</u> | A1 | 20060413 | <u>US 2004-1608</u> | 20041202 |
| <u>PRIORITY APPLN. INFO.:</u> | | | <u>US 1996-64851P</u> | P 19961223 |
| | | | <u>US 1996-780025</u> | A1 19961223 |
| | | | <u>US 1997-996422</u> | A3 19971222 |
| | | | <u>WO 1997-US22986</u> | W 19971222 |
| | | | <u>US 2001-915263</u> | A1 20010726 |
| | | | <u>US 2001-915342</u> | A3 20010727 |
| | | | <u>US 2001-915362</u> | A3 20010727 |
| | | | <u>US 2001-915379</u> | A3 20010727 |
| | | | <u>US 2001-915480</u> | A3 20010727 |
| | | | <u>US 2001-915564</u> | A3 20010727 |
| | | | <u>US 2001-916440</u> | A1 20010730 |
| | | | <u>US 2003-336687</u> | B3 20030106 |
| | | | <u>US 2003-336767</u> | A3 20030106 |

OTHER SOURCE(S): MARPAT 129:122870

AB Disclosed are compds. $R_1ZmNHnCHpR_2C(X)R_3$ [R_1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl or aryl, heteroaryl, or heterocyclic; R_2 and R_3 form a cycloalkyl, cycloalkenyl, heterocyclic, substituted cycloalkyl, or substituted cycloalkenyl ring which is optionally fused; X = oxo, thioxo, hydroxyl, thiol, or hydro; Y = CHR_4CONH where R_4 = (un)substituted alkyl, alkenyl, or alkynyl or cycloalkyl, aryl, heteroaryl, or heterocyclic; Z is $TCX'X''CO$ where T is a bond, O, S, NR_5 (R_5 = H, acyl, alkyl, aryl, or heteroaryl), X' and X'' are H, OH, or F or $X'X''$ = oxo; $m, p = 0, 1$; $n = 0, 1, 2$] which inhibit β -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Thus, 3-[[N'-(3,4-methylenedioxyphenylacetyl)-L-alaninyl]amino]-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one was prepd. by coupling of 3-(L-alaninylamino)-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one with 3,4-methylenedioxyphenylacetic acid.


IT **38559-92-1**, 4-Benzyloxyphenoxyacetic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of cycloalkyl, lactam, lactone and related compds. for inhibiting β -amyloid peptide release and/or its synthesis)

RN **38559-92-1** HCAPLUS

CN Acetic acid, [4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN

Full
Text

References

ACCESSION NUMBER: 1999:654690 HCAPLUS
 DOCUMENT NUMBER: 132:152100
 TITLE: Synthesis and antiproliferative activity of
 N-acylaspartic acid dimethyl esters
 AUTHOR(S): Schlitzer, Martin; Sattler, Isabel; Dahse, Hans-Martin
 CORPORATE SOURCE: Institut für Pharmazeutische Chemie,
 Philipps-Universität Marburg, Marburg, D-35032,
 Germany
 SOURCE: Anticancer Research (1999), 19(3A), 2117-2120
 CODEN: ANTRD4; ISSN: 0250-7005
 PUBLISHER: International Institute of Anticancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Farnesyl residues are found as a lipophilic modification of a no. of important proteins. In addn., synthetic farnesyl derivs. display a range of biol. effects. We have prepd. a series of N-acylaspartates as structural analogs of farnesylpyrophosphate in which the farnesyl residue has been replaced by a no. of different aliph. and arom. carboxylic acids and the aspartate is used as a pyrophosphate surrogate. The corresponding di-Me esters of these aspartates were assayed against different tumor cell lines. Several N-acylaspartic acid di-Me esters carrying an arom. acyl residue displayed a selective antiproliferative effect against THP-1 cells with GI50 values ranging from 7.6 to 1.3 μ M.

IT 38559-92-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and antiproliferative activity of N-acylaspartic acid di-Me esters)

RN 38559-92-1 HCAPLUS

CN Acetic acid, [4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23


THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RC 201. A1A6S

L6 ANSWER 29 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN

Full
TextCiting
References

ACCESSION NUMBER: 1972:547506 HCAPLUS
DOCUMENT NUMBER: 77:147506
TITLE: Irreversible enzyme inhibitors. 195. Inhibitors of thymidine kinase from Walker 256 carcinoma derived from thymidine 5'-acetate
AUTHOR(S): Baker, B. R.; Neenan, John P.
CORPORATE SOURCE: Dep. Chem., Univ. California, Santa Barbara, CA, USA
SOURCE: Journal of Medicinal Chemistry (1972), 15(9), 940-4
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Derivs. of thymidine 5'-acetate were good inhibitors of thymidine kinase [9002-06-6] from Walker 256 rat tumor, and may serve as prototypes for synthesis of more potent reversible and irreversible inhibitors for use as antitumor agents. The inhibition displayed was attributed in part to an interaction of the inhibitor with a hydrophilic region adjacent to the enzyme active site. Thymidine 5'- α -thionaphthyloxyacetate (I) [36983-60-5] and thymidine 5'-p-benzyloxyphenoxyacetate (II) [36983-61-6], the 2 most potent inhibitors tested, bound to the enzyme approx. as strongly as thymidine. Thymidine 5'-carbamate derivs. were inactive. I and II were prepd. by coupling the appropriate carboxylic acid with thymidine in the presence of N,N'-dicyclohexylcarbodiimide.
IT **38559-92-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 38559-92-1 HCAPLUS
CN Acetic acid, [4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RST, JS
Minopulon

L6 ANSWER 19 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN


Full
Text

References

ACCESSION NUMBER: 1992:531082 HCAPLUS
DOCUMENT NUMBER: 117:131082
TITLE: [(alkoxyphenyl)alkyl]- and
[(alkylphenyl)alkyl]pyridines and -pyridine oxides,
methods for their preparation and their use as
antiallergic agents
INVENTOR(S): Friebe, Walter Gunar; Kampe, Wolfgang; Linssen,
Marcel; Wilhelms, Otto Henning
PATENT ASSIGNEE(S): Boehringer Mannheim GmbH, Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------------|------------|
| <u>DE 4038335</u> | A1 | 19920604 | <u>DE 1990-4038335</u> | 19901201 |
| <u>CA 2099603</u> | AA | 19920602 | <u>CA 1991-2099603</u> | 19911128 |
| <u>WO 9209598</u> | A1 | 19920611 | <u>WO 1991-EP2249</u> | 19911128 |
| W: AU, BG, BR, CA, CS, FI, HU, JP, KR, NO, PL, RO, SU, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE | | | | |
| <u>AU 9189574</u> | A1 | 19920625 | <u>AU 1991-89574</u> | 19911128 |
| <u>EP 559695</u> | A1 | 19930915 | <u>EP 1991-920436</u> | 19911128 |
| <u>EP 559695</u> | B1 | 19970122 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| <u>JP 06503076</u> | T2 | 19940407 | <u>JP 1992-500329</u> | 19911128 |
| <u>AT 148115</u> | E | 19970215 | <u>AT 1991-920436</u> | 19911128 |
| <u>ES 2097822</u> | T3 | 19970416 | <u>ES 1991-920436</u> | 19911128 |
| <u>US 5399575</u> | A | 19950321 | <u>US 1993-66058</u> | 19930614 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | <u>DE 1990-4038335</u> | A 19901201 |
| | | | <u>WO 1991-EP2249</u> | A 19911128 |

OTHER SOURCE(S): CASREACT 117:131082; MARPAT 117:131082
GI



AB Certain [(alkoxyphenyl)alkyl]pyridines, [(alkylphenyl)alkyl]pyridines, or [(alkoxyphenyl)alkyl]pyridine 1-oxides or [(alkylphenyl)alkyl]pyridine 1-oxides are claimed. A process for their prepn. comprises, e.g., the alkylation of a [(hydroxyphenyl)alkyl]pyridine 1-oxide or the phenylation of a methylpyridine 1-oxide deriv. Pharmaceuticals contg. said pyridine derivs. and their use for the treatment of allergies are claimed. Alkylation of 4-[2-(4-hydroxyphenyl)ethenyl]pyridine with bromovaleronitrile gave 5-[4-[2-(4-pyridyl)ethenyl]phenoxy]valeronitrile (I) in 86 yield. The antiallergic activity of I was not tested.


IT 143052-54-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as allergy inhibitor)

RN 143052-54-4 HCAPLUS

CN Acetic acid, [4-[2-(4-pyridinyl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN

Full
TextBibliog
References

ACCESSION NUMBER: 1999:654690 HCAPLUS
 DOCUMENT NUMBER: 132:152100
 TITLE: Synthesis and antiproliferative activity of
 N-acylaspartic acid dimethyl esters
 AUTHOR(S): Schlitzer, Martin; Sattler, Isabel; Dahse, Hans-Martin
 CORPORATE SOURCE: Institut fur Pharmazeutische Chemie,
 Philipps-Universitat Marburg, Marburg, D-35032,
 Germany
 SOURCE: Anticancer Research (1999), 19(3A), 2117-2120
 CODEN: ANTRD4; ISSN: 0250-7005
 PUBLISHER: International Institute of Anticancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Farnesyl residues are found as a lipophilic modification of a no. of important proteins. In addn., synthetic farnesyl derivs. display a range of biol. effects. We have prepd. a series of N-acylaspartates as structural analogs of farnesylpyrophosphate in which the farnesyl residue has been replaced by a no. of different aliph. and arom. carboxylic acids and the aspartate is used as a pyrophosphate surrogate. The corresponding di-Me esters of these aspartates were assayed against different tumor cell lines. Several N-acylaspartic acid di-Me esters carrying an arom. acyl residue displayed a selective antiproliferative effect against THP-1 cells with GI50 values ranging from 7.6 to 1.3 μ M.

IT 38559-92-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and antiproliferative activity of N-acylaspartic acid di-Me esters)

RN 38559-92-1 HCAPLUS

CN Acetic acid, [4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT